Kala Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
09 March 2023 - 08:01AM
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage
biopharmaceutical company dedicated to the research, development
and commercialization of innovative therapies for rare and severe
diseases of the eye, today announced that it will present at the
Oppenheimer 33rd Annual Healthcare Conference. Members of Kala’s
management team will participate in a virtual fireside chat on
Wednesday, March 15, 2023 at 12:00 p.m. ET. Management will also be
available for one-on-one meetings on Wednesday, March 15, 2023.
To access the webcast and subsequent archived recording of the
fireside chat, please visit the “Presentations” section of the Kala
website at http://kalarx.com.
About Kala Pharmaceuticals, Inc.
Kala is a clinical-stage biopharmaceutical company dedicated to
the research, development and commercialization of innovative
therapies for rare and severe diseases of the eye. Kala’s
biologics-based investigational therapies utilize Kala’s
proprietary mesenchymal stem cell secretome (MSC-S) platform.
Kala’s lead product candidate, KPI-012, is a human MSC-S, which
contains numerous human-derived biofactors, such as growth factors,
protease inhibitors, matrix proteins and neurotrophic factors that
can potentially correct the impaired corneal healing that is an
underlying etiology of multiple severe ocular diseases. KPI-012 is
currently in clinical development for the treatment of persistent
corneal epithelial defect (PCED), a rare disease of impaired
corneal healing, for which it has received orphan drug designation
from the U.S. Food and Drug Administration. Kala is also targeting
the potential development of KPI-012 for the treatment of Partial
Limbal Stem Cell Deficiency and ocular manifestations of
moderate-to-severe Sjögren's and plans to initiate preclinical
studies to evaluate the potential utility of its MSC-S platform for
retinal degenerative diseases, such as Retinitis Pigmentosa and
Stargardt Disease. For more information on Kala, please
visit www.kalarx.com.
Investor Contact:
Hannah Deresiewiczhannah.deresiewicz@sternir.com
212-362-1200
KALA BIO (NASDAQ:KALA)
Historical Stock Chart
From Feb 2024 to Mar 2024
KALA BIO (NASDAQ:KALA)
Historical Stock Chart
From Mar 2023 to Mar 2024